Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) had its target price reduced by equities research analysts at HC Wainwright from $12.00 to $5.00 in a research note issued on Monday,Benzinga reports. The firm presently has a "neutral" rating on the biopharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 22.70% from the company's current price.

INO has been the topic of several other reports. Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Friday. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating for the company in a report on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Inovio Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $38.00.

Inovio Pharmaceuticals Trading Down 4.5 %

INO traded down $0.19 during trading on Monday, reaching $4.08. 554,200 shares of the company were exchanged, compared to its average volume of 403,466. Inovio Pharmaceuticals has a 52 week low of $4.07 and a 52 week high of $14.75. The firm has a 50 day moving average of $5.75 and a 200 day moving average of $8.14. The stock has a market cap of $105.79 million, a P/E ratio of -1.12 and a beta of 0.83.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth $661,000. Dimensional Fund Advisors LP acquired a new position in Inovio Pharmaceuticals in the 2nd quarter valued at approximately $605,000. Wellington Management Group LLP purchased a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $379,000. State Street Corp lifted its holdings in shares of Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock valued at $2,836,000 after buying an additional 51,414 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company's stock valued at $3,594,000 after acquiring an additional 38,833 shares during the last quarter. Institutional investors own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.